Driving the CAR-T

T cell therapies are novel and, in some cases, curative, but they also present some formidable limitations. Follow our three-part series, Driving the CAR-T, and see how a CAR-T cell therapy is engineered and produced, and how it is tested in vivo.

CAR-T Cell Therapy for Solid Tumors: Biological Activity Testing for Lot Release

The determination of biological activity of CAR-T cells plays a key role in defining the quality of the product

NOTE: This article is also available in another language (한국어).

Mar 16, 2022 |
Ulrike Herbrand, PhD

A CAR-T Study for Solid Tumors: In Vivo Pharmacology

Evaluating the efficacy and safety profile of CAR T in vivo

Mar 15, 2022 |
David Harris, PhD, Julia Schueler, DVM

CAR-T Cell Therapy for Solid Tumors: In Vitro Efficacy and Safety

Balancing cell therapy efficacy and safety during early lead optimization and development

Driving the CAR-T

CAR-T Cell Therapy for Solid Tumors: Biological Activity Testing for Lot Release

Mar 16, 2022 | Ulrike Herbrand, PhD

A CAR-T Study for Solid Tumors: In Vivo Pharmacology

Mar 15, 2022 | David Harris, PhD, Julia Schueler, DVM

CAR-T Cell Therapy for Solid Tumors: In Vitro Efficacy and Safety

Mar 14, 2022 | Sophie Vermond, Gemma Moiset, PhD

Mar 16, 2022 |
Ulrike Herbrand, PhD

Mar 15, 2022 |
David Harris, PhD, Julia Schueler, DVM

Mar 14, 2022 |
Sophie Vermond, Gemma Moiset, PhD